Reclassification of the Candida haemulonii Complex as Candida haemulonii (C. haemulonii Group I), C. duobushaemulonii sp. nov. (C. haemulonii Group II), and C. haemulonii var. vulnera var. nov.: Three Multiresistant Human Pathogenic Yeasts

E. Cendejas-Bueno; A. Kolecka; A. Alastruey-Izquierdo; B. Theelen; M. Groenewald; M. Kostrzewa; M. Cuenca-Estrella; A. Gomez-Lopez; T. Boekhout

doi:10.1128/JCM.02248-12

Reclassification of the Candida haemulonii Complex as Candida haemulonii (C. haemulonii Group I), C. duobushaemulonii sp. nov. (C. haemulonii Group II), and C. haemulonii var. vulnera var. nov.: Three Multiresistant Human Pathogenic Yeasts

E. Cendejas-Bueno, A. Kolecka, A. Alastruey-Izquierdo, B. Theelen, M. Groenewald, M. Kostrzewa, M. Cuenca-Estrella, A. Gomez-Lopez, T. Boekhout

Research output: Contribution to journal/periodical › Article › Scientific › peer-review

199 Citations (Scopus)

Abstract

The Candida haemulonii species complex is currently known as C. haemulonii groups I and II. Here we describe C. haemulonii group II as a new species, Candida duobushaemulonii sp. nov., and C. haemulonii var. vulnera as new a variety of C. haemulonii group I using phenotypic and molecular methods. These taxa and other relatives of C. haemulonii (i.e., Candida auris and Candida pseudohaemulonii) cannot be differentiated by the commercial methods now used for yeast identification. Four isolates (C. haemulonii var. vulnera) differed from the other isolates of C. haemulonii in the sequence of the internal transcribed spacer (ITS) regions of the nuclear rRNA gene operon. The new species and the new variety have a multiresistant antifungal profile, which includes high MICs of amphotericin B (geometric mean MIC, 1.18 mg/liter for C. haemulonii var. vulnera and 2 mg/liter for C. duobushaemulonii sp. nov) and cross-resistance to azole compounds. Identification of these species should be based on molecular methods, such as sequence analysis of ITS regions and matrix-assisted laser desorption ionization–time of flight mass spectrometry.

Original language	English
Pages (from-to)	3641-3651
Journal	Journal of Clinical Microbiology
Volume	50
Issue number	11
DOIs	https://doi.org/10.1128/JCM.02248-12
Publication status	Published - 2012

Access to Document

10.1128/JCM.02248-12

Fingerprint

Dive into the research topics of 'Reclassification of the Candida haemulonii Complex as Candida haemulonii (C. haemulonii Group I), C. duobushaemulonii sp. nov. (C. haemulonii Group II), and C. haemulonii var. vulnera var. nov.: Three Multiresistant Human Pathogenic Yeasts'. Together they form a unique fingerprint.

Cite this

Cendejas-Bueno, E., Kolecka, A., Alastruey-Izquierdo, A., Theelen, B., Groenewald, M., Kostrzewa, M., Cuenca-Estrella, M., Gomez-Lopez, A., & Boekhout, T. (2012). Reclassification of the Candida haemulonii Complex as Candida haemulonii (C. haemulonii Group I), C. duobushaemulonii sp. nov. (C. haemulonii Group II), and C. haemulonii var. vulnera var. nov.: Three Multiresistant Human Pathogenic Yeasts. Journal of Clinical Microbiology, 50(11), 3641-3651. https://doi.org/10.1128/JCM.02248-12

Cendejas-Bueno, E. ; Kolecka, A. ; Alastruey-Izquierdo, A. et al. / Reclassification of the Candida haemulonii Complex as Candida haemulonii (C. haemulonii Group I), C. duobushaemulonii sp. nov. (C. haemulonii Group II), and C. haemulonii var. vulnera var. nov.: Three Multiresistant Human Pathogenic Yeasts. In: Journal of Clinical Microbiology. 2012 ; Vol. 50, No. 11. pp. 3641-3651.

@article{6741cd2c27db4f1b9268fb0a84be25e1,

title = "Reclassification of the Candida haemulonii Complex as Candida haemulonii (C. haemulonii Group I), C. duobushaemulonii sp. nov. (C. haemulonii Group II), and C. haemulonii var. vulnera var. nov.: Three Multiresistant Human Pathogenic Yeasts",

abstract = "The Candida haemulonii species complex is currently known as C. haemulonii groups I and II. Here we describe C. haemulonii group II as a new species, Candida duobushaemulonii sp. nov., and C. haemulonii var. vulnera as new a variety of C. haemulonii group I using phenotypic and molecular methods. These taxa and other relatives of C. haemulonii (i.e., Candida auris and Candida pseudohaemulonii) cannot be differentiated by the commercial methods now used for yeast identification. Four isolates (C. haemulonii var. vulnera) differed from the other isolates of C. haemulonii in the sequence of the internal transcribed spacer (ITS) regions of the nuclear rRNA gene operon. The new species and the new variety have a multiresistant antifungal profile, which includes high MICs of amphotericin B (geometric mean MIC, 1.18 mg/liter for C. haemulonii var. vulnera and 2 mg/liter for C. duobushaemulonii sp. nov) and cross-resistance to azole compounds. Identification of these species should be based on molecular methods, such as sequence analysis of ITS regions and matrix-assisted laser desorption ionization–time of flight mass spectrometry.",

author = "E. Cendejas-Bueno and A. Kolecka and A. Alastruey-Izquierdo and B. Theelen and M. Groenewald and M. Kostrzewa and M. Cuenca-Estrella and A. Gomez-Lopez and T. Boekhout",

note = "Reporting year: 2012",

year = "2012",

doi = "10.1128/JCM.02248-12",

language = "English",

volume = "50",

pages = "3641--3651",

journal = "Journal of Clinical Microbiology",

issn = "0095-1137",

publisher = "American Society for Microbiology",

number = "11",

}

Cendejas-Bueno, E, Kolecka, A, Alastruey-Izquierdo, A, Theelen, B, Groenewald, M, Kostrzewa, M, Cuenca-Estrella, M, Gomez-Lopez, A & Boekhout, T 2012, 'Reclassification of the Candida haemulonii Complex as Candida haemulonii (C. haemulonii Group I), C. duobushaemulonii sp. nov. (C. haemulonii Group II), and C. haemulonii var. vulnera var. nov.: Three Multiresistant Human Pathogenic Yeasts', Journal of Clinical Microbiology, vol. 50, no. 11, pp. 3641-3651. https://doi.org/10.1128/JCM.02248-12

Reclassification of the Candida haemulonii Complex as Candida haemulonii (C. haemulonii Group I), C. duobushaemulonii sp. nov. (C. haemulonii Group II), and C. haemulonii var. vulnera var. nov.: Three Multiresistant Human Pathogenic Yeasts. / Cendejas-Bueno, E.; Kolecka, A.; Alastruey-Izquierdo, A. et al.
In: Journal of Clinical Microbiology, Vol. 50, No. 11, 2012, p. 3641-3651.

Research output: Contribution to journal/periodical › Article › Scientific › peer-review

TY - JOUR

T1 - Reclassification of the Candida haemulonii Complex as Candida haemulonii (C. haemulonii Group I), C. duobushaemulonii sp. nov. (C. haemulonii Group II), and C. haemulonii var. vulnera var. nov.: Three Multiresistant Human Pathogenic Yeasts

AU - Cendejas-Bueno, E.

AU - Kolecka, A.

AU - Alastruey-Izquierdo, A.

AU - Theelen, B.

AU - Groenewald, M.

AU - Kostrzewa, M.

AU - Cuenca-Estrella, M.

AU - Gomez-Lopez, A.

AU - Boekhout, T.

N1 - Reporting year: 2012

PY - 2012

Y1 - 2012

N2 - The Candida haemulonii species complex is currently known as C. haemulonii groups I and II. Here we describe C. haemulonii group II as a new species, Candida duobushaemulonii sp. nov., and C. haemulonii var. vulnera as new a variety of C. haemulonii group I using phenotypic and molecular methods. These taxa and other relatives of C. haemulonii (i.e., Candida auris and Candida pseudohaemulonii) cannot be differentiated by the commercial methods now used for yeast identification. Four isolates (C. haemulonii var. vulnera) differed from the other isolates of C. haemulonii in the sequence of the internal transcribed spacer (ITS) regions of the nuclear rRNA gene operon. The new species and the new variety have a multiresistant antifungal profile, which includes high MICs of amphotericin B (geometric mean MIC, 1.18 mg/liter for C. haemulonii var. vulnera and 2 mg/liter for C. duobushaemulonii sp. nov) and cross-resistance to azole compounds. Identification of these species should be based on molecular methods, such as sequence analysis of ITS regions and matrix-assisted laser desorption ionization–time of flight mass spectrometry.

AB - The Candida haemulonii species complex is currently known as C. haemulonii groups I and II. Here we describe C. haemulonii group II as a new species, Candida duobushaemulonii sp. nov., and C. haemulonii var. vulnera as new a variety of C. haemulonii group I using phenotypic and molecular methods. These taxa and other relatives of C. haemulonii (i.e., Candida auris and Candida pseudohaemulonii) cannot be differentiated by the commercial methods now used for yeast identification. Four isolates (C. haemulonii var. vulnera) differed from the other isolates of C. haemulonii in the sequence of the internal transcribed spacer (ITS) regions of the nuclear rRNA gene operon. The new species and the new variety have a multiresistant antifungal profile, which includes high MICs of amphotericin B (geometric mean MIC, 1.18 mg/liter for C. haemulonii var. vulnera and 2 mg/liter for C. duobushaemulonii sp. nov) and cross-resistance to azole compounds. Identification of these species should be based on molecular methods, such as sequence analysis of ITS regions and matrix-assisted laser desorption ionization–time of flight mass spectrometry.

U2 - 10.1128/JCM.02248-12

DO - 10.1128/JCM.02248-12

M3 - Article

SN - 0095-1137

VL - 50

SP - 3641

EP - 3651

JO - Journal of Clinical Microbiology

JF - Journal of Clinical Microbiology

IS - 11

ER -

Cendejas-Bueno E, Kolecka A, Alastruey-Izquierdo A, Theelen B, Groenewald M, Kostrzewa M et al. Reclassification of the Candida haemulonii Complex as Candida haemulonii (C. haemulonii Group I), C. duobushaemulonii sp. nov. (C. haemulonii Group II), and C. haemulonii var. vulnera var. nov.: Three Multiresistant Human Pathogenic Yeasts. Journal of Clinical Microbiology. 2012;50(11):3641-3651. doi: 10.1128/JCM.02248-12